Y-mAbs Therapeutics Inc. (YMAB): These Numbers are Too Good to be true – Invest Chronicle

Y-mAbs Therapeutics Inc. (YMAB): These Numbers are Too Good to be true

For the readers interested in the stock health of Y-mAbs Therapeutics Inc. (YMAB). It is currently valued at $13.06. When the transactions were called off in the previous session, Stock hit the highs of $13.20, after setting-off with the price of $11.94. Company’s stock value dipped to $11.94 during the trading on the day. When the trading was stopped its value was $11.50.Recently in News on May 31, 2022, Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review. Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Biologics License Application (“BLA”) for OMBLASTYS® (omburtamab) for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma has been accepted for priority review by the U.S. Food and Drug Administration (“FDA”). The FDA set an action date of November 30, 2022, under the Prescription Drug User Fee Act (“PDUFA”). The Agency also indicated in the BLA filing communication letter that it is planning to hold an advisory committee meeting in October 2022 to discuss the application. You can read further details here

Y-mAbs Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $17.90 on 01/03/22, with the lowest value was $6.50 for the same time period, recorded on 02/10/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Y-mAbs Therapeutics Inc. (YMAB) full year performance was -64.46%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Y-mAbs Therapeutics Inc. shares are logging -67.20% during the 52-week period from high price, and 100.92% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.50 and $39.82.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 524163 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Y-mAbs Therapeutics Inc. (YMAB) recorded performance in the market was -19.43%, having the revenues showcasing 10.30% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 536.24M, as it employees total of 148 workers.

Market experts do have their say about Y-mAbs Therapeutics Inc. (YMAB)

During the last month, 5 analysts gave the Y-mAbs Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 10.40, with a change in the price was noted +3.37. In a similar fashion, Y-mAbs Therapeutics Inc. posted a movement of +34.78% for the period of last 100 days, recording 688,660 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for YMAB is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical breakdown of Y-mAbs Therapeutics Inc. (YMAB)

Raw Stochastic average of Y-mAbs Therapeutics Inc. in the period of last 50 days is set at 84.72%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 76.29%. In the last 20 days, the company’s Stochastic %K was 52.46% and its Stochastic %D was recorded 43.24%.

Bearing in mind the latest performance of Y-mAbs Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -19.43%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -19.13%, alongside a downfall of -64.46% for the period of the last 12 months. The shares increased approximately by 17.03% in the 7-day charts and went down by 32.19% in the period of the last 30 days. Common stock shares were driven by 10.30% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]